Inhibrx Biosciences Inc. (INBX), a clinical-stage biopharmaceutical company, has several high-stakes catalysts on the horizon, making it a stock to watch closely.
The company is focused on developing novel biologic therapeutic candidates for life-threatening conditions based on its proprietary single-domain antibody platform. It has two drug candidates in clinical development - Ozekibart and INBRX-106.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com